MAIA Biotechnology, Inc.: director Theagene Jean-Manasse received 32,012 shares

What happened Theagene Jean-Manasse, a director, received a grant of stock options covering 32,012 shares at $0.00 on Sep 30, 2026, for $0. The filing classifies the transaction as a derivative award (code A).

Key details

• Transaction date and price: Sep 30, 2026; $0.00 per share; total $0.
• Shares owned after the transaction: not reported in the filing.
• Form filed on Oct 2, 2026; the filing does not indicate a late filing.
• Footnote F1: The stock options, granted on Sep 30, 2026 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, represent the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

Why it may matter This was a grant of stock options (a derivative award); the filing shows the options vest 100% on the grant date and are exercisable beginning as of that date. A filing does not show why the insider traded or why the company acted.